Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Mexiletine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Recipient : Lannett Company, Inc.
Deal Size : Undisclosed
Deal Type : Collaboration
Lannett Launches Mexiletine HCl Capsules
Details : Under the agreement, Lannett will primarily provide sales, marketing and distribution support for the product, for which it will receive a percentage of net profits. Other financial terms were not disclosed.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 23, 2020
Lead Product(s) : Mexiletine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Recipient : Lannett Company, Inc.
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?
Reset All
